MX2013008702A - Composiciones que contienen anticuerpos glicosilados y sus usos. - Google Patents
Composiciones que contienen anticuerpos glicosilados y sus usos.Info
- Publication number
- MX2013008702A MX2013008702A MX2013008702A MX2013008702A MX2013008702A MX 2013008702 A MX2013008702 A MX 2013008702A MX 2013008702 A MX2013008702 A MX 2013008702A MX 2013008702 A MX2013008702 A MX 2013008702A MX 2013008702 A MX2013008702 A MX 2013008702A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- compositions containing
- glycosylated antibodies
- containing glycosylated
- varying
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona las composiciones de anticuerpos, por ejemplo, los anticuerpos humanos, de estructuras de glicosilación variable, que sirven para lograr las velocidades de eliminación en suero deseadas. La invención también proporciona los métodos para modular la farmocinética de los anticuerpos, por ejemplo, de los anticuerpos humanos, y de las composiciones terapéuticas que contienen tales anticuerpos. Estos métodos se basan en la variación de las estructuras de glicosilación de los anticuerpos, por ejemplo, de los anticuerpos humanos, para lograr las velocidades de eliminación en suero deseadas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161437107P | 2011-01-28 | 2011-01-28 | |
| PCT/US2012/022742 WO2012103345A1 (en) | 2011-01-28 | 2012-01-26 | Compositions containing glycosylated antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013008702A true MX2013008702A (es) | 2013-12-06 |
Family
ID=46577528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013008702A MX2013008702A (es) | 2011-01-28 | 2012-01-26 | Composiciones que contienen anticuerpos glicosilados y sus usos. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20120195885A1 (es) |
| EP (1) | EP2668283A1 (es) |
| JP (1) | JP2014505075A (es) |
| KR (1) | KR20140114271A (es) |
| CN (1) | CN103492584A (es) |
| AU (1) | AU2012211262A1 (es) |
| BR (1) | BR112013018998A2 (es) |
| CA (1) | CA2824927A1 (es) |
| IL (1) | IL227542A0 (es) |
| MX (1) | MX2013008702A (es) |
| RU (1) | RU2013139734A (es) |
| SG (1) | SG192183A1 (es) |
| TW (1) | TW201309330A (es) |
| WO (1) | WO2012103345A1 (es) |
| ZA (1) | ZA201305504B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011032148A1 (en) * | 2009-09-14 | 2011-03-17 | Abbott Laboratories | Methods for treating psoriasis |
| EP2635601B1 (en) | 2010-11-04 | 2016-07-20 | Boehringer Ingelheim International GmbH | Anti-il-23 antibodies |
| EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
| US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
| PL3326649T3 (pl) | 2012-05-03 | 2022-04-25 | Boehringer Ingelheim International Gmbh | Przeciwciała anty-il-23p19 |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| EP2900264A4 (en) * | 2012-09-26 | 2016-05-25 | Momenta Pharmaceuticals Inc | GLYKOPROTEINZUBEREITUNGEN |
| SG11201507230PA (en) | 2013-03-12 | 2015-10-29 | Abbvie Inc | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| JP2017524359A (ja) | 2014-07-24 | 2017-08-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｉｌ−２３ａ関連疾患の処置に有用なバイオマーカー |
| SG11201701423RA (en) | 2014-09-03 | 2017-03-30 | Boehringer Ingelheim Int | Compound targeting il-23a and tnf-alpha and uses thereof |
| US20230039189A1 (en) * | 2020-01-10 | 2023-02-09 | Riken | Population of antibodies comprising homogeneous antibodies each having left-right asymmetric sugar chains, and method for producing same |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6914128B1 (en) * | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| US6902734B2 (en) * | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
| US7265085B2 (en) * | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycoconjugation methods and proteins/peptides produced by the methods |
| JP2007527696A (ja) * | 2003-04-03 | 2007-10-04 | ラボラトワール フランセ デュ フラクションヌメント エ デ バイオテクノロジーズ | 細胞機能を調節する能力が増強された治療産物 |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US20100173323A1 (en) * | 2006-06-09 | 2010-07-08 | University Of Maryland, Baltimore | Glycosylation engineered antibody therapy |
| EP2435473B1 (en) * | 2009-05-27 | 2013-10-02 | F.Hoffmann-La Roche Ag | Tri- or tetraspecific antibodies |
-
2012
- 2012-01-20 TW TW101102742A patent/TW201309330A/zh unknown
- 2012-01-26 KR KR1020137022675A patent/KR20140114271A/ko not_active Application Discontinuation
- 2012-01-26 CN CN201280006790.3A patent/CN103492584A/zh active Pending
- 2012-01-26 MX MX2013008702A patent/MX2013008702A/es not_active Application Discontinuation
- 2012-01-26 AU AU2012211262A patent/AU2012211262A1/en not_active Abandoned
- 2012-01-26 JP JP2013551336A patent/JP2014505075A/ja active Pending
- 2012-01-26 BR BR112013018998A patent/BR112013018998A2/pt not_active IP Right Cessation
- 2012-01-26 RU RU2013139734/15A patent/RU2013139734A/ru unknown
- 2012-01-26 SG SG2013057344A patent/SG192183A1/en unknown
- 2012-01-26 EP EP12738765.2A patent/EP2668283A1/en not_active Withdrawn
- 2012-01-26 WO PCT/US2012/022742 patent/WO2012103345A1/en active Application Filing
- 2012-01-26 US US13/359,250 patent/US20120195885A1/en not_active Abandoned
- 2012-01-26 CA CA2824927A patent/CA2824927A1/en not_active Abandoned
-
2013
- 2013-07-18 IL IL227542A patent/IL227542A0/en unknown
- 2013-07-19 ZA ZA2013/05504A patent/ZA201305504B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012103345A1 (en) | 2012-08-02 |
| BR112013018998A2 (pt) | 2016-08-09 |
| SG192183A1 (en) | 2013-09-30 |
| TW201309330A (zh) | 2013-03-01 |
| KR20140114271A (ko) | 2014-09-26 |
| EP2668283A1 (en) | 2013-12-04 |
| US20120195885A1 (en) | 2012-08-02 |
| ZA201305504B (en) | 2015-08-26 |
| IL227542A0 (en) | 2013-09-30 |
| CN103492584A (zh) | 2014-01-01 |
| JP2014505075A (ja) | 2014-02-27 |
| RU2013139734A (ru) | 2015-03-10 |
| CA2824927A1 (en) | 2012-08-02 |
| AU2012211262A1 (en) | 2013-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013008702A (es) | Composiciones que contienen anticuerpos glicosilados y sus usos. | |
| AU2018253544A1 (en) | Methods for treating or preventing asthma by administering an IL-4R antagonist | |
| PH12018500707A1 (en) | Anti-human cd19 antibodies with high affinity | |
| NZ707086A (en) | Anti-cd40 antibodies and methods of use | |
| WO2012149356A3 (en) | Anti-cd40 antibodies and methods of use | |
| MX2021002406A (es) | Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica. | |
| AU2016219704A1 (en) | Anti-Notch1 antibodies | |
| MX336682B (es) | Anticuerpos contra csf-1r humanos y usos de los mismos. | |
| MX356337B (es) | Anticuerpos contra csf-1r humano y sus usos. | |
| EA024842B9 (ru) | Соединения в качестве модуляторов протеинкиназы pi3k | |
| TN2012000462A1 (en) | Anti-cd40 antibodies | |
| MY184628A (en) | Afucosylated anti-fgfr2iiib antibodies | |
| TN2013000378A1 (en) | Anti - sclerostin antibody crystals and formulations thereof | |
| PH12014502406A1 (en) | Anti-il-23p19 antibodies | |
| WO2014052360A3 (en) | Glycoprotein preparations | |
| MX2014010537A (es) | Moduladores de receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dermicas. | |
| PH12015502829A1 (en) | Lectin-like oxidized ldl receptor1 antibodies and methods of use | |
| WO2014205302A3 (en) | Lectin-like oxidized ldl receptor1 antibodies and methods of use | |
| MX2016004540A (es) | Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda). | |
| MX2014001766A (es) | Anticuerpos de neuregulina y sus usos. | |
| TN2015000277A1 (en) | Bmp-6 antibodies | |
| MX2016002931A (es) | Moduladores del receptor x hepatico (lxr). | |
| MX2016002930A (es) | Moduladores del receptor x hepatico (lxr). | |
| WO2014194053A3 (en) | Carbohydrate compounds for nutritional and therapeutic use | |
| TN2011000517A1 (en) | Fused pyrimidineone compounds as trpv3 modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |